Moderna, Inc. stock is up ~60% YTD on cancer vaccine trial data, 2026 readouts, and 2025 financials. Click for this updated ...
Morning Overview on MSN
FDA declines to review Moderna’s mRNA flu shot application
The Food and Drug Administration’s refusal to even file Moderna’s application for its first mRNA-based flu shot is more than a bureaucratic hiccup. It is a rare public rebuke of a company that helped ...
The Department of Health and Human Services (HHS) is winding down its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority (BARDA), the agency announced ...
mRNA Synthesis and Manufacturing Market to Witness a Leap by Leaching CAGR of ~6% By The End Of 2030
Global mRNA Synthesis and Manufacturing Market OverviewThe global mRNA synthesis and manufacturing market is projected to grow at a compound annual growth rate of approximately 6% during the forecast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results